Justice GCC
ar ع
  • Home
  • Legislation
  • Courts
  • Law Firms
  • Deals
Reading: Emirates Drug Establishment First to Approve Ultomiris for Proteinuria in IgA Nephropathy
Share
Justice GCCJustice GCC
Font ResizerAa
  • Legislation
  • Courts
  • Law Firms
  • Deals
Search
  • Home
  • Legislation
  • Courts
  • Law Firms
  • Deals
  • About
  • Corrections
  • Editorial Policy
  • Contact
Justice GCC > Legislation > Emirates Drug Establishment First to Approve Ultomiris for Proteinuria in IgA Nephropathy
Legislation

Emirates Drug Establishment First to Approve Ultomiris for Proteinuria in IgA Nephropathy

NewsDesk
Last updated: November 11, 2026 7:17 pm
NewsDesk
Share
Emirates approves Ultomiris for IgA nephropathy | AI-Generated Image
SHARE

The Emirates Drug Establishment has conditionally approved a new indication for AstraZeneca’s Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy who face a high risk of disease progression. The regulatory body announced the decision on November 10, 2026, underscoring the UAE’s commitment to accelerating patient access to innovative therapies while maintaining rigorous standards for safety and efficacy. This marks the first worldwide approval for the complement inhibitor in this specific use, building on the medicine’s existing registration in the country since 2022 for several rare diseases.

Primary immunoglobulin A nephropathy is an immune-mediated condition in which abnormal deposits of immunoglobulin A trigger inflammation in the kidneys, often leading to a progressive decline in organ function over time. A review published in Seminars in Nephrology highlighted considerable geographic variation in incidence, with rates rising from west to east across Eurasia due in part to genetic factors and differences in screening and biopsy practices. Data cited in a JAMA Network article placed the annual incidence between 0.76 and 2.2 per 100,000 people depending on the region, with prevalence estimates reaching 54 to 63 per 100,000 in the United States alone.

Interim results from the phase 3 I CAN trial, published in the New England Journal of Medicine, showed that ravulizumab produced a 46.6 percent reduction in the 24-hour urine protein-to-creatinine ratio at week 34, compared with a 5.6 percent reduction in the placebo arm. The adjusted between-group difference reached 43.4 percent, meeting the primary endpoint with statistical significance, and the safety profile remained consistent with previous uses of the therapy. According to the Emirates Drug Establishment, the conditional approval followed a comprehensive scientific assessment that balanced the need for timely innovation against requirements for quality and evidence of benefit.

Ruqaya Aqeel Al Bastaki, Acting Executive Director of the Medical Products Regulation Sector at the Emirates Drug Establishment, said the approval reflects the Establishment’s commitment to strengthening the pharmaceutical sector’s readiness to respond to scientific developments and emerging treatments, reinforcing the UAE’s position among the leading countries in pharmaceutical regulation. She added that the decision aligns with the strategic priorities of the We the UAE 2031 vision, which seeks to enhance competitiveness in healthcare and advance research and development. The framework adopted by the authority enables rapid yet evidence-based responses to new therapies for complex conditions.

The medicine, administered as an intravenous infusion every eight weeks, joins a growing portfolio of options available to nephrologists managing glomerular diseases in the UAE. Records from the Emirates Drug Establishment indicate that Ultomiris was first registered locally in 2022 for indications including paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome. Expansion to immunoglobulin A nephropathy broadens its reach to a condition that accounts for a substantial share of primary glomerular diagnoses globally.

Sameh El Fangary, Gulf Cluster President at AstraZeneca, described the conditional approval as an important step towards expanding the treatment options available to eligible patients in the UAE. He stated that the company looks forward to continuing its collaboration with partners in the country to support access to this treatment, helping improve outcomes and enhance the quality of care. The pharmaceutical group is conducting further follow-up in the I CAN study to verify longer-term clinical benefits.

Epidemiological assessments published in Health.com place worldwide prevalence at roughly 60 cases per 100,000 people, with new cases occurring at rates of two to three per 100,000 annually in many populations. Higher reported incidence in East Asia, sometimes exceeding four new cases per 100,000, partly reflects systematic urine screening programmes that detect mild cases earlier than in other regions. The Emirates Drug Establishment’s latest action adds to a series of regulatory steps that have positioned the UAE among early adopters of advanced therapies for kidney disorders.

Share This Article
Email Copy Link Print
ByNewsDesk
Justice GCC NewsDesk is the desk responsible for Justice GCC's daily news coverage, monitoring and reporting developments across the Gulf from official sources, including national news agencies and government communications. Its focus is accurate, timely and factual coverage of the region.
Previous Article Saudi Court Sentences Kenyan Migrant Worker to 100 Lashes for Extramarital Birth
Next Article Baker McKenzie Recruits Data Protection Expert Kelly Hagedorn in London Lateral Move

Popular Posts

Saudi Court Sentences Kenyan Migrant Worker to 100 Lashes for Extramarital Birth

A Saudi court sentenced Kenyan domestic worker Esther Wanja Muthoni to 100 lashes after she gave birth outside marriage in…

By
NewsDesk
3 Min Read
Baker McKenzie Recruits Data Protection Expert Kelly Hagedorn in London Lateral Move

Baker McKenzie announced the appointment of Kelly Hagedorn as a cybersecurity and…

3 Min Read
Saudi Prosecution Halts Case Against Sri Lankan National Sivarasa Anojan

Saudi Arabia's Public Prosecution discontinued its case against Sivarasa Anojan on November…

4 Min Read

More News

VAT Group Closes Atonarp Acquisition Financed by CHF 110 Million Bilateral Loan

VAT Group completed the acquisition of Atonarp Inc. on November…

November 18, 2026

Natroshvili Expands Business Portfolio With UAE Legal Advisory Launch

David Natroshvili, ranked the most influential…

November 17, 2026

Iran Condemns Bahrain’s Life Sentences for Shia Clerics as Rights Abuse

Iran's Foreign Ministry on November 17,…

November 17, 2026

Bahraini Court Sentences 64 to Life in Prison Over Alleged Iran Links

A Bahraini court on November 16…

November 17, 2026

Qatar Justice Ministry Advances Full Automation Under 2025-2030 Legal Strategy

On February 17, 2026, Qatar's Minister…

November 17, 2026

Recommended for You

Legislation

Twelve Saudi Agencies Establish Strict Standards for Recreational Weapon and Firework Imports

Saudi Arabia introduced a unified regulatory guide approved by 12 government entities on October 3 2026 that imposes detailed licensing…

4 Min Read
Legislation

SocGen CEO Expects Regulation to Delay But Not Halt AI-Driven Banking Transformation

Societe Generale CEO Slawomir Krupa said this week that stringent regulatory requirements will slow artificial intelligence adoption in banking while…

3 Min Read
Legislation

UAE Cybersecurity Teams Neutralise 750,000 Attack Attempts on Critical Infrastructure

The UAE blocked 750,000 cyberattack attempts with energy and education sectors the most targeted, the Cybersecurity Council reported on August…

4 Min Read
Legislation

UAE Ministry Imposes Dh207,000 Fines on Companies for Unjustified Price Rises After Extensive Inspections

The UAE Ministry of Economy issued Dh207,000 in fines for unauthorized price increases on March 10, 2026 after conducting 7,105…

3 Min Read

Categories

  • Legislation
  • Courts
  • Law Firms
  • Deals

Quick Links

  • About
  • Corrections
  • Editorial Policy
  • Contact
Justice GCC
© 2026 Justice GCC. Published by Peninsula News Group LLC. All rights reserved.
  • Privacy Policy
  • Terms of Use
  • Contact
Welcome to Foxiz

Sign in to your account

Username or Email Address
Password

Lost your password?